Swedish Orphan Biovitrum AB (publ) Q4 2022 Earnings Report $30.48 0.00 (0.00%) As of 02/24/2025 Earnings HistoryForecast Swedish Orphan Biovitrum AB (publ) EPS ResultsActual EPS$0.43Consensus EPS $0.44Beat/MissMissed by -$0.01One Year Ago EPSN/ASwedish Orphan Biovitrum AB (publ) Revenue ResultsActual Revenue$559.09 millionExpected Revenue$481.32 millionBeat/MissBeat by +$77.77 millionYoY Revenue GrowthN/ASwedish Orphan Biovitrum AB (publ) Announcement DetailsQuarterQ4 2022Date2/8/2023TimeN/AConference Call ResourcesBIOVF Earnings History Swedish Orphan Biovitrum AB (publ) Earnings HeadlinesBerenberg Bank Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)February 18, 2025 | markets.businessinsider.comKepler Capital Keeps Their Hold Rating on Swedish Orphan Biovitrum AB (0MTD)February 8, 2025 | markets.businessinsider.comNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long run … that's a good thing.February 25, 2025 | Weiss Ratings (Ad)RBC Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)February 6, 2025 | markets.businessinsider.comSwedish Orphan Biovitrum targets high single-digit growth in 2025 amid robust pipeline advancementsFebruary 6, 2025 | msn.comSwedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2024 Earnings Call TranscriptFebruary 5, 2025 | seekingalpha.comSee More Swedish Orphan Biovitrum AB (publ) Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum AB (publ)? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum AB (publ) and other key companies, straight to your email. Email Address About Swedish Orphan Biovitrum AB (publ)Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.View Swedish Orphan Biovitrum AB (publ) ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Price Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock Rally Upcoming Earnings NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025)Snowflake (2/26/2025)TJX Companies (2/26/2025)Autodesk (2/27/2025)Canadian Imperial Bank of Commerce (2/27/2025)Dell Technologies (2/27/2025)Royal Bank of Canada (2/27/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.